July 21-24, 2026
Sheraton Boston Hotel
Boston, Massachusetts

Scientific Committee Cochairs

Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

Scientific Committee Members:

Raffaele Colombo, Zymeworks Inc., Vancouver, BC, Canada
Christina Curtis, Stanford University, Stanford, California
Danette L. Daniels, Foghorn Therapeutics, Cambridge, Massachusetts
Jayesh Desai, Peter MacCallum Cancer Centre, Melbourne, Australia
Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, Texas
Marjorie C. Green, Merck & Co., Kenilworth, New Jersey
Norbert Kraut, Boehringer Ingelheim, Vienna, Austria
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, New York
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York
William Pao, Revelio Therapeutics, Inc., New York, New York
Lilli Petruzzelli, Genentech, San Francisco, California
Trevor J. Pugh, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada
Ramesh Rengan, University of Washington School of Medicine, Seattle, Washington
Mike Sathekge, University of Pretoria, Pretoria, South Africa
Kurt A. Schalper, Yale University, New Haven, Connecticut
Andrew M. Scott, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia
William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
Lin Shen, Peking University Cancer Hospital, Beijing, China
Kevan M. Shokat, University of California, San Francisco, California
Yu Shyr, Vanderbilt University Medical Center, Nashville, Tennessee
Jean-Charles Soria, Amgen Oncology, Thousand Oaks, California
Mario Sznol, Yale University, New Haven, Connecticut
Chris H. Takimoto, The START Center for Cancer Research, Menlo Park, California
Samra Turajlic, Cancer Research UK Manchester Institute, Manchester, United Kingdom
Naoto T. Ueno, University of Hawai’i Cancer Center, Honolulu, Hawaii
Matthew G. Vander Heiden, Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts
Paul Workman, The Institute of Cancer Research, London, United Kingdom
Li Yan, US Chinese Anti-Cancer Association, Martinez, California

This groundbreaking global conference will redefine the future of oncology drug development by challenging conventional paradigms and catalyzing innovation across disciplines. Bringing together a diverse and influential community—including leaders from biotech, pharma, academia, regulatory agencies, technology, venture capital, and patient advocacy—this conference is being launched to spark bold ideas and foster transformative collaborations.

Far beyond traditional didactic sessions, the conference will feature immersive and interactive formats to create dynamic networking opportunities and facilitate real-time problem-solving. Attendees will explore cutting-edge science, novel technologies, and emerging frameworks that promise to revolutionize how cancer therapies are discovered, developed, and delivered.

Objectives:

• Highlight emerging drug mechanisms and first-in-class targets
• Examine the impact of breakthroughs in cellular and molecular biology
• Showcase transformative tools, platforms, and AI-driven approaches in drug discovery
• Advance next-generation clinical trial designs and innovative endpoints
• Explore forward-thinking regulatory pathways to accelerate development timelines
• Foster strategic partnerships through curated networking experiences
• Facilitate networking and professional development opportunities to inspire and support oncology-focused entrepreneurs

Join us to shape the next era of oncology therapeutics.

#AACRdrugdev26